Blog
  by

AliveCor’s Kardia Mobile More Effective Than Traditional Atrial Fibrillation Diagnosis

AliveCor recently released the results of several studies of their smartphone enabled ECG, Kardia Mobile. The studies demonstrated the technologies’ capabilities to detect atrial fibrillation (AFib). One of the studies, published in Circulation which is the journal of the American Heart Association, showed that the technology was much more likely to catch AFib.

The study included approximately 1,000 participants aged 65 and older with no previous AFib diagnosis. The participants were separated into 2 groups, one of which received traditional care, while the other group used the Kardia Mobile technology to perform twice weekly ECGs. After one year, 19 AFib cases were caught in the group using Kardia Mobile, in comparison to only 5 in the control group.

In addition to this study, AliveCor also released three other studies, two conducted in Hong Kong, and one that was conducted with Cleveland Clinic. In all of the studies, the Kardia Mobile performed very well, diagnosing patients who had previously been undiagnosed, often at a greater frequency than the control groups. The study conducted at Cleveland Clinic, the Kardia Mobile demonstrated 96.6% sensitivity and a 94% specificity compared to the use of a 12-lead EKG among the same patient cohort.

mHealth App Launched To Support Heart Failure Patients

Once a patient is diagnosed with any chronic care condition, disease management becomes a critical challenge. For Heart Failure (HF) this includes complex medication regimens that must be balanced with changes to patients’ diet and lifestyle.  This change management process can be difficult, which has created market demand for patient-friendly, effective tools to help patients better manage their condition.

To remedy this, Massachusetts General Hospital recently launched a study of a cardiac care management app called Heart Habits. This app not only tracks patients’ symptoms and provides educational content, but also prompts patients with surveys multiple times a week and allows for messaging between patients and physicians to review pertinent information as needed.

As mobile enabled solutions for both diagnosis and management of cardiac conditions continue to evolve and gain further traction in the market, it is important for all health systems to consider how they may play a role in their organizations’ cardiovascular strategy. Uncertain if mHealth apps fit into your organization’s strategy, or of the timing of this type of an investment?  Refer to the Sg2 publication “Unsure What and When to Invest in Virtual Health? Sg2 Has a Model for That!” Not an Sg2 member? Contact us to learn more.

  • Share
  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube